CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishIntroduction: Inflammatory skin reactions are the most common issue in Cetuximab-treated patients. Many evidences show the correlation with NB-UVB exposure, but the mechanisms are not completely understood. The aim of this study is the evaluation of the effects of NB-UVB exposure on inflammatory cytokines modulation during EGFR immunotherapy. Materials and methods: Human immortalized keratinocytes, HaCaT cells, were treated with 10 g/ml of Cetuximab for 24 hrs and NB-UVB exposed. Viability, ROS production and pro-inflammatory cytokines geneexpression and release were assessed. An additional, in vivo evaluation of Minimal Erythema Dose in Cetuximabtreated patients was performed. Results: NB-UVB exposure activates the inflammatory skin response in HaCaT cells, inducing the overexpression of pro-inflammatory mediators. Reduced cells viability, ROS production and expression and release of selected cytokines after Cetuximab-treatment. The co-treatment, with NB-UVB and Cetuximab, show the recovery with baseline conditions. In vivo evaluation underline that patient’s skin reactions are not changed after NB-UVB exposure. Conclusion: In conclusion, NB-UVB doesn't exacerbate papulopustular reactions developed during anti-EGFR treatment, both in vivo and in vitro evaluations. A better understanding of this relationship, between NB-UVB exposure and dermatological side effects, could throw a new light on sun exposure limitation, improving Cetuximabtreated patients QoL and favoring therapeutic adherence.
| Titolo: | Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure | |
| Autori: | ||
| Data di pubblicazione: | 2018 | |
| Rivista: | ||
| Abstract: | Introduction: Inflammatory skin reactions are the most common issue in Cetuximab-treated patients. Many evidences show the correlation with NB-UVB exposure, but the mechanisms are not completely understood. The aim of this study is the evaluation of the effects of NB-UVB exposure on inflammatory cytokines modulation during EGFR immunotherapy. Materials and methods: Human immortalized keratinocytes, HaCaT cells, were treated with 10 g/ml of Cetuximab for 24 hrs and NB-UVB exposed. Viability, ROS production and pro-inflammatory cytokines geneexpression and release were assessed. An additional, in vivo evaluation of Minimal Erythema Dose in Cetuximabtreated patients was performed. Results: NB-UVB exposure activates the inflammatory skin response in HaCaT cells, inducing the overexpression of pro-inflammatory mediators. Reduced cells viability, ROS production and expression and release of selected cytokines after Cetuximab-treatment. The co-treatment, with NB-UVB and Cetuximab, show the recovery with baseline conditions. In vivo evaluation underline that patient’s skin reactions are not changed after NB-UVB exposure. Conclusion: In conclusion, NB-UVB doesn't exacerbate papulopustular reactions developed during anti-EGFR treatment, both in vivo and in vitro evaluations. A better understanding of this relationship, between NB-UVB exposure and dermatological side effects, could throw a new light on sun exposure limitation, improving Cetuximabtreated patients QoL and favoring therapeutic adherence. | |
| Handle: | http://hdl.handle.net/11564/699451 | |
| Appare nelle tipologie: | 1.1 Articolo in rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| epidermal-growth-factor-immunotherapy-exploring-the-effects-of-nbuvb-exposure-2161-0681-1000348.pdf | PDF editoriale | Open Access Visualizza/Apri |
Copyright © 2021